All Monoclonal Antibodies articles – Page 5
-
NewsSino Biological and BioGeometry: advancing protein R&D
The expansion of Sino Biological and BioGeometry’s strategic partnership promises to accelerate drug discovery.
-
ArticleA novel class of drug candidates for neurodegenerative diseases
At AAIC 2024, AC Immune unveiled a new class of antibody drug conjugates, called morADC (Morphomer® antibody drug conjugate). In this Q&A, CEO of AC Immune, Andrea Pfeifer, discusses how morADC uses the capabilities of the company’s two discovery platforms to combine two highly selective molecules, resulting in drug candidates ...
-
ArticleRapid delivery of toxicological material
With increasingly rapid timelines for achieving IND-ready processes, a bottleneck has emerged in the provision of toxicology data to support INDs for new therapeutics and hence delivery of FIH studies, explains Alejandro Fernandez Martell and James Berrie from Lonza.
-
NewsmRNA vaccine provides enhanced protection against mpox
The mRNA vaccine candidate more effectively limited symptoms and disease duration in non-human primates.
-
NewsPancreatic cancer suppressed by humanised anti-CKAP4 antibody
The humanised antibody, Hv1Lt1, showed promising results in pancreatic cancer mouse models.
-
ArticleCombatting disease with antibody drug conjugates
Tune into this episode where we investigate how antibody drug conjugates can be optimised, as well as the future of the field.
-
ArticleExploring the potential of ADCs beyond oncology
Antibody Drug Conjugates (ADCs) are already deployed as part of the roster of oncology treatments, but here, Mike Ward, Head of Thought Leadership for Life Sciences & Healthcare, Clarivate, looks into their potential to help treat a whole range of other diseases and conditions. He discusses the barriers and enablers ...
-
NewsReprogramming B cells to produce custom antibodies
The new technique could be adapted to produce a wide range of antibodies to combat chronic conditions like HIV.
-
ArticleSupercharging conventional monoclonal antibodies
In this Q&A, Krishna Polu and Dennis Pedersen, senior leaders of Commit Biologics, which is backed by Novo Holdings and Bioqube Ventures, elucidate how their technology differs from other existing therapeutic platforms and highlight its implications for the treatment of both cancer and autoimmune disease.
-
ArticleUnleashing the potential of lab-grown recombinant polyclonal antibodies
In this Q&A, Sheila Keating, Vice President of Immunology at GigaGen, a Grifols company, explains how its developments in recombinant polyclonal antibody therapies are helping to build a pipeline of highly effective treatments for a wide range of diseases, including the hepatitis B virus.
-
NewsTargeting drug resistance in HER2-positive breast cancer models
Researchers discovered that HER2-positive breast cancer drugs must target both HER2 and EGFR receptors to eradicate disease.
-
ArticleLeveraging ADCs in precision oncology strategy
In this Q&A, senior leaders at Caris Life Sciences discuss how the company is advancing precision medicine by integrating ADCs into patient-specific cancer treatment plans, focusing on novel target discovery through comprehensive molecular profiling and clinico-genomic data.
-
NewsNew study challenges assumptions about the development of RA
Scientists have discovered that each rheumatoid arthritis patient possesses a unique and diverse set of ACPAs.
-
NewsImproved method to control the generation of dopaminergic neurons
A synthetic antibody selectively activates the Wnt signalling pathway and directs stem cells to differentiate into neurons.
-
ArticleUnlocking the potential of antibody drug conjugates
Zymeworks’ Dr Paul Moore, Dr Raffaele Colombo and Dr Jamie Rich discuss how advancements in ADCs are redefining cancer treatment. They elucidate the innovative strategies that are being developed to improve drug stability and how personalised medicine approaches are optimising outcomes for individual cancer patients, offering new hope across several ...
-
ArticleDeveloping the next generation of antibody drug conjugates
In this Q&A, Léo Marx, Medicinal Chemistry Project Manager at Debiopharm, details how the therapeutic window of ADCs can be impacted, how we can overcome the challenges associated with achieving site-specific bioconjugation, and other essential considerations for optimising ADC performance.
-
ArticlePioneering the advancement of pre-targeted radioimmunotherapies
Although pre-targeting is still in its infancy, it has immense potential to increase state-of-the-art radioligand therapies. In this Q&A, PreTT reveals how their pre-targeted RLTs surpass traditional methods, transforming cancer treatment.
-
NewsEpstein-Barr virus: new targets for vaccine design and treatment
A lab generated monoclonal antibody prevented EBV infection and EBV lymphomas in rodent models and could have future clinical applications.
-
NewsIdentification of antibodies to target the NA globular head domain
The study's findings could be applied to the development of new vaccine and therapeutic strategies for influenza.
-
NewsKey insights into vaccine development for herpesviruses
Researchers found that the D48 antibody neutralised HSV-1 virus infection, which could lead to broad-spectrum drug and vaccine development.